Insider Buying: FocalTherics (NASDAQ:FOCL) General Counsel Buys $23,750.00 in Stock

FocalTherics (NASDAQ:FOCL) General Counsel Sanket Shah purchased 5,000 shares of the company’s stock in a transaction dated Friday, August 14th. The shares were acquired at an average price of $4.75 per share, for a total transaction of $23,750.00. Following the purchase, the general counsel directly owned 72,500 shares of the company’s stock, valued at approximately $344,375. The trade was a 7.41% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.

FocalTherics Stock Up 2.3%

Shares of FocalTherics stock opened at $4.36 on Thursday. The stock has a market cap of $163.41 million, a price-to-earnings ratio of -4.23 and a beta of -0.04. The company has a quick ratio of 0.99, a current ratio of 1.60 and a debt-to-equity ratio of 1.79. The firm has a 50 day moving average of $5.37. FocalTherics has a 52 week low of $1.30 and a 52 week high of $6.40.

FocalTherics (NASDAQ:FOCL) last released its earnings results on Friday, August 14th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.19). FocalTherics had a negative return on equity of 248.00% and a negative net margin of 56.26%.The company had revenue of $13.20 million for the quarter. As a group, research analysts anticipate that FocalTherics will post -0.78 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have commented on FOCL shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of FocalTherics in a research report on Monday. Mizuho set a $15.00 price objective on FocalTherics and gave the company an “outperform” rating in a report on Friday, July 17th. Wall Street Zen cut FocalTherics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Piper Sandler reaffirmed a “neutral” rating and set a $4.00 target price on shares of FocalTherics in a report on Friday, August 14th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of FocalTherics in a research report on Tuesday, June 2nd. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $7.75.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. SmartHarvest Portfolios LLC purchased a new stake in FocalTherics in the first quarter valued at $38,000. Lido Advisors LLC purchased a new position in shares of FocalTherics during the 1st quarter valued at about $40,000. Kovack Advisors Inc. acquired a new position in shares of FocalTherics in the 4th quarter valued at about $53,000. Leonteq Securities AG purchased a new stake in shares of FocalTherics in the fourth quarter worth about $313,000. Finally, Flax Pond Capital LLC acquired a new stake in FocalTherics during the fourth quarter worth about $2,623,000. 62.74% of the stock is currently owned by institutional investors and hedge funds.

About FocalTherics

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.